Mechanistic insights into radiopharmaceutical therapies: Spatially-resolved computational model coupling radioligand pharmacokinetics with tumour dynamics
Preprint
Abstract
Radiopharmaceutical therapies (RPTs) offer targeted radiation delivery to tumour cells, yet treatment outcomes vary substantially across patients while dosing protocols remain largely uniform. Translating mechanistic insight into improved protocols requires models that couple radioligand (RL) pharmacokinetics, spatial tumour biology, and radiation response — a combination that existing models have not yet fully achieved. We developed a hybrid discrete-continuous model coupling a cellular automaton for spatially resolved tumour dynamics to a pharmacokinetic compartment model tracking RL from injection to tumour-cell receptor binding and internalization, linked to an energy deposition and linear-quadratic radiobiological model. Simulating treatment of heterogeneous tumours across a range of conditions, we find that treatment outcome is governed primarily by tumour size and receptor expression levels and is relatively insensitive to the injected amount. By decoupling radiobiological resistance from RL delivery effects — which are spatially correlated in real tumours but separated in our model — we show that hypoxic radioresistance alone is insufficient to prevent cure, identifying compromised RL delivery, rather than intrinsic radioresistance, as the dominant mechanism of hypoxic treatment failure. These findings provide a mechanistic basis for patient stratification by receptor expression, yield a new size-based rationale for multi-injection protocols, and demonstrate that spatially resolved modelling can reveal treatment principles inaccessible to non-spatial approaches.Keywords
Funding Information
- Canadian Institutes of Health Research (Project Grant PJT-162216)
This publication has 67 references indexed in Scilit:
- Oxygenation Status of Malignant Tumors vs. Normal Tissues: Critical Evaluation and Updated Data Source Based on Direct Measurements with pO2 MicrosensorsApplied Magnetic Resonance, 2021
- Clinical and Pre-clinical Methods for Quantifying Tumor Hypoxia2019
- Theranostics for Advanced Prostate Cancer: Current Indications and Future DevelopmentsEuropean Urology Oncology, 2019
- The rate of oxygen utilization by cellsFree Radical Biology and Medicine, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A mathematical model for brain tumor response to radiation therapyJournal of Mathematical Biology, 2008
- HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumptionCell Metabolism, 2006
- The Use of Hybrid Cellular Automaton Models for Improving Cancer Therapy2004
- Diffusion of Oxygen in Plasma and Blood1976
- The mechanism of the induction by radiation of chromosome aberrations inTradescantiaJournal of Genetics, 1942